News

Charnwood Molecular - Tom McInally final

Charnwood Molecular is pleased to welcome Tom McInally to its group of strategic partners.

Tom has over 30 years’ experience as a medicinal chemist in the pharmaceutical industry at Fisons, Astra Charnwood and AstraZeneca in the UK. He has worked in various therapeutic areas including cardiovascular and respiratory. He led a team which integrated parallel synthesis and purification techniques into in-house LO programmes and subsequently led the chemistry team in a 6 year research collaboration with the Japanese pharmaceutical company DaiNippon Sumitomo to discover novel Toll-Like Receptor 7 agonists targeting various respiratory diseases with a lead compound entering clinical trials.

In 2011 he joined the University of Nottingham as a Business Science Fellow in Medicinal Chemistry. He has taken the lead role in teaching and mentoring 4thyr MSci project students in the principles of medicinal chemistry to enable them to undertake the GSK sponsored drug discovery project entitled “Drug discovery for Fibrotic diseases”.

Tom will work alongside the Medicinal Chemistry team at Charnwood, providing valuable insight and advice on the progress of our current projects.

Charnwood Molecular has signed a collaboration agreement with computational chemistry specialist, CCR, a Structure Based Design Consultancy headed by John King-Underwood.

By partnering with CCR, Charnwood Molecular is able to further extend its offering for effective drug discovery. This partnership will deliver contract services which help chemists design, discover and optimise small molecules against particular project targets.

CCR provides the benefits of 25 years of experience in drug discovery gained in big pharma, biotech and consultancy, encompassing many different projects and target classes. Since its conception in 2003, CCR has enabled many of its clients to achieve significant growth and success.

CCR will assist Charnwood Molecular in providing the following skills to medicinal chemistry projects:

• Molecular Modelling
• Structure Based Design
• Computational Medicinal Chemistry
• Informatics and Data Handling

Commenting on the partnership with Charnwood, John King-Underwood said: “We work with a range of partners to enhance and meet clients’ research efforts. We are delighted to be working with Charnwood Molecular at an exciting time when they are growing and working with more and more small companies needing to access first class discovery chemistry contract services. We all look forward to delivering our partnership to clients across the world.”

Dr Robin Wilkes, Director of Business Development at Charnwood Molecular stated: “CCR’s reputation, experience in tackling computational problems and proactive approach makes them the ideal collaborator for the fast-moving medicinal chemistry projects that we are increasingly working on. By adding these services and expertise to the Charnwood Molecular portfolio, we have further broadened our capabilities as a collaborative and enabling company to support drug discovery organisations.”

conference1

We are in the process of organising our conference and events schedule for the coming months.

So far we will be present at the following UK events:

Event: The Romark Medicinal Chemistry Symposium
Date: 15 May 2017
Venue: Liverpool
Attending: Professor Steven Allin
________________________________________________________________
Event: LATi 2017 Life Sciences Showcase
Date: 17 May 2017
Venue: NTU Clifton Campus, Nottingham
Attending: Professor Steven Allin
________________________________________________________________
Event: Targeting the Ubiquitin Pathway – Ligases
Date: 19 May 2017
Venue: Birmingham
Attending: Dr James Hitchin
________________________________________________________________
Event: Frontiers in Epigenetic Chemical Biology
Date: 22-23 May 2017
Venue: London
Attending: Dr James Hitchin
________________________________________________________________
Event: Alternative Models for Drug Discovery – How has the Landscape Evolved?
Date: 15 June 2017
Venue: Cambridge
Attending: Professor Steven Allin
________________________________________________________________

If you would like to meet any of our representatives at these events, please email:
info@charnwood-molecular.com

conference1

We are in the process of organising our conference and events schedule for the coming months.

So far we will be present at the following events:

Event: The Romark Medicinal Chemistry Symposium
Date: 15 May 2017
Venue: Liverpool
Attending: Professor Steven Allin
________________________________________________________________
Event: LATi 2017 Life Sciences Showcase
Date: 17 May 2017
Venue: NTU Clifton Campus, Nottingham
Attending: Professor Steven Allin
________________________________________________________________
Event: Targeting the Ubiquitin Pathway – Ligases
Date: 19 May 2017
Venue: Birmingham
Attending: Dr James Hitchin
________________________________________________________________
Event: Frontiers in Epigenetic Chemical Biology
Date: 22-23 May 2017
Venue: London
Attending: Dr James Hitchin
________________________________________________________________
Event: RSC Anglo-Nordic MedChem Symposium
Date: 12-14 June 2017
Venue: Copenhagen, Denmark
Attending: Dr James Hitchin
________________________________________________________________
Event: World Preclinical Congress: Mastering MedCHem
Date: 12-16 June 2017
Venue: Boston, USA
Attending: Dr Robin Wilkes
________________________________________________________________
Event: Alternative Models for Drug Discovery – How has the Landscape Evolved?
Date: 15 June 2017
Venue: Cambridge
Attending: Professor Steven Allin
________________________________________________________________

If you would like to meet any of our representatives at these events, please email:
info@charnwood-molecular.com

We are looking for a Business Development Executive to join our expanding team.

logo and new strap

This exciting BD Executive role requires a committed self-starter who is driven to respond proactively to business opportunities and creatively grow the CML business. The role requires excellent communication, problem-solving and influencing skills as well as the ability to work effectively as part of a small but growing team.

Key Responsibilities

• Revenue generation for assigned territories to agreed levels
• Account management of client accounts
• New business development, to grow and enhance the CML business in assigned territories
• Arranging client meetings and attending business events
• Reporting progress through our business development infrastructure

Applicant Requirements

We envisage candidates for this exciting position will have some, if not all, of the following attributes:

• Scientific background, to BSc level or beyond
• Previous experience in a business development role within a chemical, pharmaceutical or life sciences environment
• Excellent communication skills
• Willingness to travel as required to develop business opportunities

Salary & Location

We offer a competitive salary and benefits, including a company pension scheme. Dependent on experience this role may be company or home office based, though frequent attendance at the company’s sites would be expected.

Deadline for Applications

We request applications are submitted by 15th May 2017 – please email a covering letter & CV to:
recruitment@charnwood-molecular.com

For an informal discussion of the role, please email in the first instance:
r.wilkes@charnwood-molecular.com

Charnwood Molecular is sponsoring a trek across the Sahara Desert in aid of St Lukes Hospice in Winsford, Cheshire.

Charnwood Molecular - Lucy Tunstall

Keele University PhD student, Lucy Tunstall, whose work on the development of novel anti-malarials is co-funded by Charnwood Molecular, is undertaking the trek as part of a fund-raising effort for St Lukes Hospice in Winsford. Lucy is a keen fund raiser and this is just the latest of a series of challenges that she has undertaken to raise funds for the hospice, the most recent of which was a sky dive, raising over £400.

The Saharan trek takes place in difficult terrain and covers a 50km stretch of the desert. Lucy is aiming to achieve a fund raising target of £1600 for the trek, which takes place in October 2017.

“I am so pleased that Charnwood Molecular has decided to sponsor me in my efforts in the Sahara” she said. “I’m really looking forward to the challenge – it will be great to take a little chemistry with me to Africa!” she added.

If you would like to contribute to Lucy’s Just Giving page, please follow the link:

https://www.justgiving.com/fundraising/Lucy-Tunstall1

Charnwood Molecular has recently been awarded the Crédit d’Impôt Recherche (CIR) approval from the French Ministère de l’Éducation nationale, de l’Enseignement supérieur et de la Recherche.

CIR logo

A key benefit of this accreditation is to allow our French clients to benefit from significant tax relief on drug discovery research undertaken in partnership with Charnwood Molecular from 2017 through 2019.

For more information on how Charnwood Molecular can bring its “Excellence in Chemistry” to your research projects, please visit: www.charnwood-molecular.com, or contact our Director of Business Development, Dr. Robin Wilkes (r.wilkes@charnwood-molecular.com).

More information on the accreditation can be found here: http://www.education.gouv.fr/

dr-james-hitichin-and-dr-robin-wilkes

Charnwood Molecular was recently featured in an extensive article in the Nottingham Post.

The news article outlines our plans for expansion in 2017, alongside a profile piece on new Head of Medicinal Chemistry, Dr James Hitchin and an insight on the business’ plans from Business Development Director, Dr Robin Wilkes (both pictured above at the BioCity lab).

The full article can be read here:

Charnwood Molecular expansion – Article in Nottingham Post

dr-james-hitchin-new-head-of-medicinal-chemistry-at-charnwood-molecular

We have appointed Dr James Hitchin as the new Head of Medicinal Chemistry to lead our research services laboratories at BioCity, Nottingham.

Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team. James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy. Most recently he was Senior Medicinal Chemist at the Cancer Research UK Manchester Institute, where he worked on various target classes, including kinases and epigenetic targets from hit identification right through to lead optimization and beyond.

“I am looking forward to the challenge of leading Charnwood Molecular’s Medicinal Chemistry division”, states James. “We are experiencing significant growth in our chemistry services business, including an increase in demand for the medicinal chemistry research that we undertake at the BioCity laboratories. Charnwood’s success is based upon providing extremely high quality, yet cost-effective, solutions for medicinal chemistry projects, becoming the partner of choice for an increasingly diverse client base.”

The appointment will further strengthen Charnwood Molecular’s reputation for excellence in synthesis and customer service, as well as expanding our strength in medicinal chemistry.

James joins a team with existing expertise in a wide range of therapeutic areas, including oncology, obesity, immunology, respiratory disease, inflammation and the treatment of cardiovascular diseases.

James has an impressive publication record covering areas as diverse as the discovery and optimisation of novel allosteric inhibitors of IDH1, the discovery of a highly potent series of TLR7 agonists, and the development and evaluation of selective, reversible LSD1 inhibitors. James’ publication work continues, with a further four papers expected in the short term in high impact journals. He has also been named as an inventor of three patents this year describing the development of inhibitory compounds for both PARG and autotoxin, as well as running a third year medicinal chemistry course for students at the University of Manchester.

Dr Robin Wilkes, Business Development Director of Charnwood Molecular commented: “We are thrilled that James has joined the Charnwood team. We aim to improve clients’ medicinal chemistry initiatives through creativity and innovation and James’ appointment will undoubtedly help in this regard. His appointment is an important advancement towards our plans for future growth, further enhancing the experience of our talented medicinal chemistry group.”

Charnwood Molecular’s work on early stage chemical development for medicinal chemistry projects recently featured in an extensive Chemistry World article, in an interview with Dr David Lathbury.

david-lathbury-portrait

The divide between contract medicinal chemistry and chemical development needs to be bridged.

That’s the opinion of Dr David Lathbury, who is working with Charnwood Molecular, on its process research and development services for small to mid-sized pharma and biotechnology clients.

The idea is to combine early stage chemical development research with medicinal chemistry projects. By getting chemical development involved earlier, it means the chemistry is better understood before it’s transferred either to another CRO or an in-house team for larger scale production.

‘That way, you have a much better idea of what you’re handing over, and the other side know what they are getting into”, states Dr Lathbury.

The full Chemistry World article, written by Dr Phillip Broadwith, Business Editor of Chemistry World, can be read here: Chemistry World Article.